$CNTB News

Canaccord Genuity Initiates Coverage On Connect Biopharma Hldgs with Buy Rating, Announces Price Target of $6

Cantor Fitzgerald Initiates Coverage On Connect Biopharma Hldgs with Overweight Rating, Announces Price Target of $4

Connect Biopharma Hldgs Q1 EPS $(0.34) Misses $(0.28) Estimate, Sales $169.000K

Connect Biopharma: New Market Opportunity In The Emergency Setting

Connect Biopharma Proceeds With Phase 2 Enrollment For Rademikibart Following Interim Efficacy Analysis

Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update

Connect Biopharma Hldgs Q4 EPS $(0.27) Beats $(0.30) Estimate

BTIG Reiterates Buy on Connect Biopharma Hldgs, Maintains $10 Price Target

Connect Biopharma Holdings Limited (CNTB) Discusses Phase 3 Atopic Dermatitis Study Results and Updates on Rademikibart Development Transcript

Connect Biopharma touts rapid IV rademikibart FEV1 gains; Phase 3 atopic dermatitis data impresses

Connect Biopharma Announces $20.2 Million Private Placement Financing

Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study

Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD

Connect Biopharma Holdings shares are trading higher after the company announced preliminary results for its Phase 1 clinical pharmacology study evaluating intravenous (IV) rademikibart, its anti-interleukin-4-receptor alpha antibody. Also, the company announced a $20.2 million private placement of 6.1 million shares.

Connect Biopharma Holdings shares are trading higher after the company announced preliminary results for its Phase 1 clinical pharmacology study evaluating intravenous (IV) rademikibart, its anti-interleukin-4-receptor alpha antibody. Also, the company announced a $20.2 million private placement of 6.1 million shares.

Connect Biopharma Raises ~$20.2M Via Private Placement Of 6.13M Shares At $3.25 Each

Connect Biopharma Reports Topline Preliminary Results For Phase 1 Clinical Pharmacology Study Evaluating IV Rademikibart, Next-Gen, Anti-IL-4Rα Antibody

Connect Biopharma Presents Results From Phase 3 52-Week Study In Patients With AD Conducted By Simcere Pharma At 2026 AAD Annual Meeting

Connect Biopharma Touts “Next-Gen Dupixent” Rademikibart, Near-Term Asthma/COPD Readouts

Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meeting